Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPI-589 in ALS
NCT02460679Phase 2Completed
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Jan 2016
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of EPI-589 in amyotrophic lateral sclerosis (ALS), sponsored by PTC Therapeutics, Inc.. Started Jan 2016; status: completed.
02
Drugs
EPI-589
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT02460679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02460679.